|
|
|
|
|
|
|
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
Daniel Spratt, MD
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.
|
|
|
|
|
Long-term Survival in Men with Gleason Score 9-10 Treated with Prostate Brachytherapy and External Beam Irradiation
This study attempts to address an important question: whether high risk prostate cancer is better treated with radical prostatectomy or combined radiation therapy following neoadjuvant ADT. The authors retrospectively reviewed the clinical course in patients with high risk prostate cancer as defined by the D’Amico risk categories, who underwent radical prostatectomy or combined external-beam radiation and high dose-rate brachytherapy.
|
|
|
|
|
Ten Year Treatment Outcomes of Radical Prostatectomy vs External Beam Radiation Therapy vs Brachytherapy for 1,503 Patients with Intermediate Risk Prostate Cancer
Comparison of definitive therapy of localized prostate cancer is of great interest to both urologists, radiation oncologists and medical oncologists. In this study the authors present data on 10-year treatment outcomes of radical prostatectomy vs. external beam radiation therapy vs. brachytherapy for patients with intermediate risk prostate cancer.
|
|
|
|
|
Risk of Secondary Bladder Cancer After High Dose Rate Brachytherapy for Prostate Cancer
Treatment-induced secondary cancers are well described following radiotherapy for prostate cancer. While the majority of the literature has focused on external beam radiotherapy, the risk associated with brachytherapy appears to be somewhat less.
|
|
|
|
|
Salvage High-Intensity Focused Ultrasound For Locally Recurrent Prostate Cancer after Low-Dose-Rate Brachytherapy: Oncologic and Functional Outcomes
According to the EAU-ESTRO-SIOG 2018 guidelines, the biochemical disease-free survival for Gleason 6 prostate cancer at 5 years ranges from 71-93% and at 10 years from 65-85%. However, there is a lack of studies evaluating salvage therapies for locally recurrent prostate cancer after low-dose-rate brachytherapy.
|
|
|
|
|
Analysis of External Beam Radiation Therapy, Low-Dose Rate and Combined External Beam with Brachytherapy in Prostate Cancer
In the Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) Trial, combined external beam radiation therapy and low-dose rate brachytherapy prostate boost improved biochemical control compared to external beam prostate boost, but caused greater physician reported toxicity. In this abstract, for the reasons listed above, the authors compare patient reported outcomes between EB-LDR and EBRT to inform treatment selection.
|
|
|
|
|
Validation of the 2015 Prostate Cancer Gleason Grade Groups for Predicting Cancer Control Outcomes after Radical Prostatectomy
In this retrospective analysis, the authors examined the utility of the Gleason grade groups (GGG) (1-5), correlation to Gleason scores of 6, 7(3+4), 7(4+3), 8, and >8, respectively. This was performed on the GGG of radical prostatectomies.
|
|
|
|
|
Should Gleason Score at the Positive Surgical Margin appear on the Pathology Report for Robot-Assisted Radical Prostatectomy?
In this prostate cancer surgical therapy session the argument that Gleason score at the surgical margin should be reported on pathology reports after robotic radical prostatectomy was presented.
|
|
|
|
|
|
|
|
|
|
|
|
